Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since August, ...
Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 ...
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed ...
Faced with a slumping stock and growing competition in the next-generation sequencing market it continues to dominate, Illumina this past week committed to delivering high single-digit revenue ...
SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire ...
On Monday, Illumina, Inc. (NASDAQ:ILMN) agreed to acquire Standard BioTools’ (NASDAQ:LAB) subsidiary, SomaLogic. Following the announcement of the acquisition, Standard BioTools’ stock experienced a ...
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, in partnership with Illumina, a leader in DNA sequencing and array-based technologies, offers a promising new ...
The last three years have been anything but static for next-generation sequencing (NGS) companies. Several competitors have launched new sequencing technologies that have taken direct, and often ...
Next-generation sequencing (NGS) has moved away from expensive runs and complicated workflows into a new era where benchtop instruments prioritize sustainability, accessibility, accuracy, and speed.
Vossman discusses the genomics landscape, as well as next-generation sequencing (or NGS), and the Model Project, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback